TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT05510908

Intervention type: OTHER
Intervention: Non-Interventional
Description: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
Study: NCT05510908

Intervention type: OTHER
Intervention: Non-Interventional
Description: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Intervention type: OTHER
Intervention: Non-Interventional
Description: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Intervention type: OTHER
Intervention: Non-Interventional Follow-up
Description: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Intervention type: OTHER
Intervention: Non-Interventional Follow-up
Description: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT06400472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4170156
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4170156
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4170156
Description: Intravenous
Study: NCT05928117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Pregnant women will be given training to cope with the fear of childbirth.
Study: NCT06571591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-L03 Group 1
Description: tablets, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-L03 Group 2
Description: tablets, QD, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: tablet, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: tablet, QD, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: tablet, QD, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: tablets, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: tablets, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: tablets, oral administration
Study: NCT05552261

Intervention type: DRUG
Intervention: Cenegemin in the DEFENDO Study
Description: Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial.
Study: NCT03184935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decitabine
Description: Decitabine，20mg/m\^2/d
Study: NCT04759586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Given PO
Study: NCT03184935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine，20mg/m\^2/d
Study: NCT05943392

Intervention type: OTHER
Intervention: EEG recording
Description: EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli

Intervention type: OTHER
Intervention: Psychophysics (behavioural experiments)
Description: Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
Study: NCT04850196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
Study: NCT04759586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO
Study: NCT04850196

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
Study: NCT06243939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus
Description: Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
Study: NCT04899999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial reward graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health reward graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms graphic message
Description: Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
Study: NCT05364970

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VR_Training_1PP
Description: Immersive VR scenario of physical training with avatar embodiment

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VR_Training_3PP
Description: Immersive VR scenario of physical training without avatar embodiment
Study: NCT05427448

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of amyloid and pTau blood biomarkers
Description: Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
Study: NCT05951790

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
Study: NCT06499740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted SAFETY-A for PC
Description: This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual delivered in participating clinics.
Study: NCT04743492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
Study: NCT05857241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD)
Description: D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period.
Study: NCT06575465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle nutrition, culture and physical activity workshops
Description: The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care patients receive in their primary health care
Study: NCT06134375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
Study: NCT06574984

Intervention type: DRUG
Intervention: Turoctocog alfa
Description: Turoctocog alfa was administered intravenously.
Study: NCT05958121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase Ia)
Description: Intravenous infusions in escalating dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase Ib)
Description: Treatment at MTD and/or RDE (Phase Ib)
Study: NCT05603650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumineux Oral Essentials rinse
Description: mouthrinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lumineux Oral Essentials rinse
Description: mouthrinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine rinse
Description: mouthrinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listerine rinse
Description: mouthrinse
Study: NCT04763174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Coping Skills Training for Symptom Management (mCOPE)
Description: mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
Study: NCT04711109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05164341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metreleptin
Description: Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05958121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase II)
Description: Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
Study: NCT05707377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib capsules administered orally.
Study: NCT06382870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
Study: NCT04892550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denneroll traction
Description: The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Program
Description: The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Program
Description: The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
Study: NCT05707377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib capsules administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib capsules administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus capsules administered orally.
Study: NCT06575374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given by mouth or intravenously
Study: NCT06574139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstained
Description: Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Like
Description: Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
Study: NCT06481397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCObind (Onco-Seraph) 100 Filter
Description: The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
Study: NCT06284954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empasiprubart IV
Description: Intravenous infusion with Empasiprubart IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Intravenous infusion with Placebo IV
Study: NCT06280352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom made Total Knee Arthroplasty
Description: Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functionally aligned robotically assisted total knee arthroplasty
Description: Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
Study: NCT05931276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: a dialyzable, beta-1 selective beta blocker